Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment